Reunion Neuroscience

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing innovative therapeutics for underserved mental health disorders. Our lead program, luvesilocin, is a clinically validated, purpose-designed 5-HT2A agonist advancing through a deliberate development strategy intended to generate learnings across mood and anxiety disorders, inform future indications, and maximize long-term patient impact.

We are advancing luvesilocin across multiple indications, including generalized anxiety disorder (GAD), adjustment disorder (AjD), major depressive disorder (MDD), and postpartum depression (PPD). Reunion is also developing RE245, a discovery-stage, non-psychedelic 5-HT2A agonist designed to provide therapeutic mental health benefits for chronic conditions without causing hallucinations or cardiotoxicity.

We envision a day when depression and other mental health conditions aren't just disorders that can be managed, but instead are curable. Backed by experienced neuroscience drug developers, scientific leaders, and industry veterans, we are advancing a new generation of therapeutics designed to improve outcomes for the millions of people whose needs are not met by today's standard of care.